Balyasny Asset Management LLC Seagen Inc. Call Options Transaction History

Balyasny Asset Management LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2023 Nov 14, 2023	BUY	$191.51 - $216.16 $32.9 Million - $37.2 Million	171,900 Added 134.19%	300,000 $63.6 Million
Q2 2023 Aug 14, 2023	BUY	$187.64 - $206.25 $13.8 Million - $15.2 Million	73,500 Added 134.62%	128,100 $24.7 Million
Q1 2023 May 15, 2023	SELL	$127.59 - $203.08 $15.3 Million - $24.4 Million	-120,300 Reduced 68.78%	54,600 $11.1 Million
Q4 2022 Feb 14, 2023	BUY	$117.37 - $139.17 $12.2 Million - $14.4 Million	103,700 Added 145.65%	174,900 $22.5 Million
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $15.7 Million - $20.9 Million	-115,800 Reduced 61.93%	71,200 $9.74 Million
Q2 2022 Aug 15, 2022	BUY	$108.81 - $179.33 $2.07 Million - $3.41 Million	19,000 Added 11.31%	187,000 $33.1 Million
Q1 2022 May 16, 2022	BUY	$119.61 - $157.85 $20.1 Million - $26.5 Million	168,000 New	168,000 $24.2 Million
Q3 2021 Nov 15, 2021	SELL	$142.45 - $169.82 $24.1 Million - $28.7 Million	-169,000 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$135.08 - $161.1 $17.6 Million - $20.9 Million	130,000 Added 333.33%	169,000 $26.7 Million
Q1 2021 May 17, 2021	BUY	$137.51 - $190.8 $5.36 Million - $7.44 Million	39,000 New	39,000 $5.42 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.